| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0001541 | Ovarian follicle development | Decreases phenotype | PMID:23740543 |
| GO:0001552 | Ovarian follicle atresia | Increases phenotype | PMID:23740543 |
| GO:0007204 | Positive regulation of cytosolic calcium ion concentration | Increases phenotype | PMID:30503853 |
| GO:0007409 | Axonogenesis | Decreases phenotype | PMID:18564821 |
| GO:0007567 | Parturition | Decreases phenotype | PMID:23740543 |
| GO:0008219 | Cell death | Increases phenotype | PMID:28115069 |
| GO:0030841 | Positive regulation of intermediate filament polymerization | Increases phenotype | PMID:6361548 |
| GO:0044849 | Estrous cycle | Decreases phenotype | PMID:26410608 |
| GO:2000866 | Positive regulation of estradiol secretion | Decreases phenotype | PMID:26410608 |
| GO:2000872 | Positive regulation of progesterone secretion | Affects phenotype | PMID:26410608 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.